Across TCGA pan-cancer cohorts, BMS1P15 Mutation is linked to patient survival in 1 of 34 cancer types, making it a survival-associated BMS1P15 data layer compared with 20 for mass-spec protein.
The strongest signal is observed in lung adenocarcinoma (LUAD), where higher BMS1P15 Mutation is associated with worse disease-free survival. In most high-consensus cancer types, elevated BMS1P15 expression acts as an unfavorable survival marker.
LUAD are the cancer types where BMS1P15 Mutation most reproducibly stratifies survival.